Imatinib mesylate induced immune thrombocytopenia.
Rajappa
Senthil
S
Varadpande
Lalit
L
Paul
Tara Roshni
TR
Digumarti
Raghunadharao
R
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use*; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000209:etiology*; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate